Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
US7560105B1 · kind B1 · utility
1Cited by
0References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2000 |
| Grant date | Jul 14, 2009 |
| Priority date | — |
| Expiry date | Feb 1, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel methods for immunotherapy. The invention provides immune cells and methods to generate them, with the capacity to at least in part reduce an immune response in a host. In one aspect, the invention provides a method for generating a dendritic cell with the capacity to tolerize a T-cell for antigen the T-cell was specific for including culturing peripheral blood monocytes from an individual to differentiate into dendritic cells, activating the dendritic cells in the presence of a glucocorticoid hormone and loading the activated dendritic cell with the antigen the T-cell was specific for.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.